Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.26 USD
Change Today +0.11 / 1.20%
Volume 717.7K
VNDA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

vanda pharmaceuticals inc (VNDA) Key Developments

Vanda Pharmaceuticals Inc. Announces Nominating/Corporate Governance Committee Changes

Vanda Pharmaceuticals Inc. announced that on March 16, 2015, Steven K. Galson, M.D., M.P.H. notified the Board of Directors of the company that he did not intend to stand for re-election at the company's 2015 Annual Meeting of Stockholders so that he may devote his full time efforts to his other commitments. The Board has appointed Richard Dugan, a current director, to succeed Dr. Galson as a member of the Nominating/Corporate Governance Committee of the Board, effective upon the expiration of Dr. Galson's term.

Vanda Pharmaceuticals Inc. Announces Top-Line Results of the Phase II Proof of Concept Clinical Study

Vanda Pharmaceuticals Inc. announced top-line results of the Phase II proof of concept clinical study investigating the safety and efficacy of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis. Tradipitant, formerly known as VLY-686, is a neurokinin 1 receptor antagonist under clinical investigation for the treatment of chronic pruritus in patients with atopic dermatitis. The pre-specified primary endpoint of the Phase II proof of concept clinical study was the change from baseline on the Visual Analog Scale (VAS) for itch. Due to high placebo effect, there was no significant difference from placebo on this pre-specified endpoint, however, Vanda believes this proof of concept study was informative, in that through subsequent analyses, it has discovered an exposure response relationship and further observed a significant and clinically meaningful response across several pruritus related outcomes evaluated in individuals with higher blood plasma levels of tradipitant. This is not unexpected given that all the assessments related to pruritus are significantly associated with the itch sensation the patient is experiencing at that time. Based on the data Vanda examined across the study, lower blood plasma levels of tradipitant may be below a threshold of efficacy to ameliorate the itch sensation in patients.

Vanda Pharmaceuticals Inc. Announces Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Sales Guidance for the Year 2015

Vanda Pharmaceuticals Inc. announced consolidated financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company’s total revenues were $15.4 million, compared to $8.8 million for the fourth quarter of 2013. Net income was $69.7 million compared to a net loss of $7.7 million for the fourth quarter of 2013. Diluted net income per share was $1.77, compared to a net loss per share of $0.23 for the fourth quarter of 2013. Non-GAAP total revenues were $7.6 million, compared to $2.0 million for the fourth quarter of 2013. Non-GAAP net loss was $13.5 million compared to $12.7 million for the fourth quarter of 2013. Non-GAAP diluted net loss per share was $0.36, compared to $0.38 for the fourth quarter of 2013. Income from operations was $69.693 million against loss from operations of $7.791 million a year ago. For the year, the company’s total revenues were $50.2 million, compared to $33.9 million for 2013. Net income was $20.2 million compared to a net loss of $21.1 million for 2013. Diluted net income per share was $0.55, compared to a net loss per share of $0.69 for 2013. Non-GAAP total revenues were $19.4 million, compared to $7.1 million for 2013. Non-GAAP net loss was $80.0 million compared to $40.9 million for 2013. Non-GAAP Diluted net loss per share was $2.30, compared to $1.35 for 2013. Income from operations was $20.062 million against loss from operations of $21.200 million a year ago. The company expects ombined net product sales from both HETLIOZ and Fanapt of between $95 million and $110 million for the year 2015. HETLIOZ net product sales of between $40 million to $45 million and Fanapt net product sales of between $55 million to $65 million.

Vanda Pharmaceuticals, Inc. to Report Q4, 2014 Results on Feb 19, 2015

Vanda Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 10:00 AM, US Eastern Standard Time on Feb 19, 2015

Vanda Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 19, 2015

Vanda Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 19, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $9.26 USD +0.11

VNDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,686 GBp -5.00
Bristol-Myers Squibb Co $65.26 USD +0.26
Eli Lilly & Co $73.58 USD +0.14
Pernix Therapeutics Holdings Inc $10.21 USD -0.09
Sanofi €91.69 EUR +0.31
View Industry Companies
 

Industry Analysis

VNDA

Industry Average

Valuation VNDA Industry Range
Price/Earnings 16.8x
Price/Sales 6.9x
Price/Book 2.4x
Price/Cash Flow 17.2x
TEV/Sales 5.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.